Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: An Italian Sarcoma Group Trial ISG/OS-1

Journal of Clinical Oncology

Volumn 30, Issue 17, 2012, Pages 2112-2118

  Ferrari, Stefano ^a   Ruggieri, Pietro ^a   Cefalo, Graziella ^b   Tamburini, Angela ^d   Capanna, Rodolfo ^e   Fagioli, Franca ^f   Comandone, Alessandro ^g   Bertulli, Rossella ^b   Bisogno, Gianni ^h   Palmerini, Emanuela ^a   Alberghini, Marco ^a   Parafioriti, Antonina ^c   Linari, Alessandra ^f   Picci, Piero ^a   Bacci, Gaetano ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^g GRADENIGO HOSPITAL   (Italy)

^h UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE;

ACUTE KIDNEY FAILURE; ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; ARTICLE; CARDIOMYOPATHY; CHILD; CONTROLLED STUDY; DRUG EXCRETION; DRUG FATALITY; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HISTOPATHOLOGY; HUMAN; ITALY; LEUKOPENIA; LIMB SALVAGE; LIMB TUMOR; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NONMETASTATIC OSTEOSARCOMA; OSTEOSARCOMA; OVERALL SURVIVAL; PATIENT COMPLIANCE; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; CISPLATIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FEMUR; HUMANS; HUMERUS; IFOSFAMIDE; MALE; METHOTREXATE; OSTEOSARCOMA; TIBIA;

EID: 84863928403     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.4420     Document Type: Article

References (20)

1. Marina N, Gebhardt M, Teot L, et al: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9:422-441, 2004 (Pubitemid 39014554)
2. Hogendoorn PC, ESMO/EUROBONET Working Group, Athanasou N, et al: Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v204-v213, 2010 (suppl 5)
3. Ferrari S, Smeland S, Mercuri M, et al: Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: A joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 23:8845-8852, 2005 (Pubitemid 46211531)
4. Enneking WF, Dunham W, Gebhardt MC, et al: A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res 286:241-245, 1993
5. Picci P, Bacci G, Campanacci M, et al: Histologic evaluation of necrosis induced by chemotherapy: Regional mapping of viable and nonviable tissue. Cancer 56:1515-1521, 1985 (Pubitemid 15228493)
6. Jaffe N, Paed D, Farber S, et al: Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy. Cancer 31:1367-1373, 1973
7. Lewis IJ, Weeden S, Machin D, et al: Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma: European Osteosarcoma Intergroup. J Clin Oncol 18:4028-4037, 2000 (Pubitemid 32038394)
8. Eselgrim M, Grunert H, Kühne T, et al: Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials. Pediatr Blood Cancer 47:42-50, 2006 (Pubitemid 43787907)
9. Fuchs N, Bielack SS, Epler D, et al: Long-term results of the co-operative German-Austrian-Swiss Osteosarcoma Study Group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 9:893-899, 1998 (Pubitemid 28440449)
10. Le Deley MC, Guinebretière JM, Gentet JC, et al: SFOP OS94: A randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer 43:752-761, 2007
11. Smeland S, Müller C, Alvegard TA, et al: Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: Prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 39:488-494, 2003 (Pubitemid 36173693)
12. Smeland S, Bruland OS, Hjorth L, et al: Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years. Acta Orthop 82:211-216, 2011
13. Meyers PA, Schwartz CL, Krailo MD, et al: Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival - A report from the Children's Oncology Group. J Clin Oncol 26:633-638, 2008 (Pubitemid 351264359)
14. Bielack SS, Kempf-Bielack B, Delling G, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776-790, 2002 (Pubitemid 34111386)
15. Bacci G, Longhi A, Versari M, et al: Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 106:1154-1161, 2006
16. Hauben EI, Weeden S, Pringle J, et al: Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer 38:1218-1225, 2002 (Pubitemid 34603483)
17. Bacci G, Bertoni F, Longhi A, et al: Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity: Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer 97:3068-3075, 2003 (Pubitemid 36676262)
18. Lewis IJ, Nooij MA, Whelan J, et al: Improvement in histologic response but not survival in osteosarcomapatients treated with intensified chemotherapy: A randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 99:112-128, 2007
19. Bacci G, Ferrari S, Bertoni F, et al: Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 Protocol: An updated report. J Clin Oncol 18:4016-4027, 2000 (Pubitemid 32038393)
20. Marina N, Bielack S, Whelan J, et al: International collaboration is feasible in trials for rare conditions: The EURAMOS experience. Cancer Treat Res 152:339-353, 2010